Canntab & FSD Pharma Make Cannabis More Palatable for Doctors
December 20th, 2018
Cannabinoids have the potential to radically transform the pharmaceutical industry. For example, new studies suggest that cannabis legalization could reduce opioid prescriptions by about six to 12 percent. The problem is that medical cannabis is very different from pharmaceutical drugs—it’s hard for physicians to prescribe treatments that lack consistency or may be metabolized differently between patients.
Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.
In this article, we will look at Canntab’s partnership strategy, which could open the door to near-term revenue opportunities.
Near-term Revenue Potential
Canntab submitted an application to become a licensed producer under the ACMPR back in October. Once the license is granted, the company will be able to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures compared to a new purpose-built facility. The application is a step in the right direction, but could take months for Health Canada to review and approve the application.
In the meantime, the company partnered with FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) in September to begin manufacturing its tablets. The agreement calls for FSD Pharma to assist Canntab in obtaining a license to sell cannabis and provide space at its Cobourg facility near Toronto. Canntab will in turn provide all of the necessary equipment and provide a royalty on products that are manufactured within the facility.
The company delivered manufacturing equipment to FSD Pharma’s Cobourg plant in September that will enable the production of more than 1.5 million tablets per day. Under the terms of the deal, these products will be sold by both FSD Pharma—where it receives half of all profit from sales through its channels—or through Canntab’s channels—where FSD Pharma will receive 3.5 percent of the selling price.
Building Value with Partners
Canntab’s partnership with FSD Pharma is just one of several partnerships that the company has signed over the past several months.
The company’s other partnerships include
- Dr. Don Garbuz, MD: The company signed a binding term sheet with Dr. Garbuz, a leading orthopedic surgeon, to conduct a clinical study on his patients using Canntab’s sustained release tablets for pain reduction.
- Emblem Corp. (TSX-V: EMC) (OTC: EMMBF): The company is collaborating with Emblem to formulate its cannabinoid-based product portfolio. Dissolution testing indicated that its extended release tablets deliver over 12 hours.
- Labsco Promedic SA: The company agreed to form a joint venture with Labsco Promedic to distribute its products in Mexico.
The agreements expand the company’s distribution into parts of Latin America and Europe, as well as pave the way for robust clinical data to support its claims to reduce pain and operate over an extended period of time.
Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) represents a compelling investment opportunity. By providing doctors with a better way to prescribe cannabis, the company’s products could open the door to a much larger addressable patient population. The near-term agreement with FSD Pharma helps get products into the market, while numerous distribution agreements could lead to near-term commercialization opportunities.
For more information, visit the company’s website.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.